A growth investor's lament

Don't let your down days put you off your game

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

I have a confession to make. I've been having somewhat of a Foolish identity crisis of late. My predicament is indubitably linked to a crisis of confidence I've been experiencing. I'm just full of crises these days.

Sometimes I just feel like the world's worst investor.

Who am I?
I'm a relatively young investor, so my long time horizon affords me a relatively high risk tolerance.

I've always been attracted to small-cap growth stocks with multibagger potential, which is also why I was a Rule Breakers subscriber before becoming a full-time Fool. Fortunately, the sector that I'm most interested in — technology — is chock-full of Rule Breakers in the making. Unfortunately, sometimes they get punished.

Lesson learned
One of the most important lessons that I've learned from Fool co-founder David Gardner is that lofty P/E ratios alone don't paint the whole picture. True Rule Breakers that have disruptive, multibagger potential deserve that premium valuation.

For example, two of the best-performing Rule Breakers picks, Baidu (Nasdaq: BIDU) and Chipotle Mexican Grill (NYSE: CMG) , have long sported lofty multiples. Baidu's P/E is no stranger to triple-digit territory.

BIDU P/E Ratio Chart

BIDU P/E Ratio data by YCharts

If high multiples alone had kept you away, then you missed out on this performance.

BIDU Chart

BIDU data by YCharts

On the flip side, high multiple stocks are particularly prone to volatility as the market tries to figure them out. That price discovery process can lead to severe multiple compression if growth prospects are questioned. Layman's translation: The stocks can tank. Hard.

This most recent earnings season has been so brutal that it's shaken me to my growth-investing core in a rather demoralising fashion. Maybe the grass is greener on the other value-investing side.

A tale of three sell-offs
Three of my personal Rule Breaking holdings — Riverbed Technology (Nasdaq: RVBD), MAKO Surgical (Nasdaq: MAKO), and Universal Display (Nasdaq: PANL) — have gotten absolutely crushed this season. Season's beatings, indeed.


P/E the Day Before Earnings

P/S the Day Before Earnings

Sales Growth (MRQ)

Next Day's Performance

Riverbed Technology 69.2 6.1 11.5% (29%)
MAKO Surgical NM 20.6 50.7% (37%)
Universal Display 575.1 29.6 31.5% (10%)

Sources: SEC filings, author's calculations. MRQ = most recent quarter. NM = not meaningful.

Riverbed's quarter was definitely disappointing, with product sales only inching up by a measly 4%. The company is looking to expand beyond its niche WAN optimisation market and transition into a multiproduct company to reinvigorate sales growth. Riverbed still has some legitimate hurdles to clear, and investors have reason to question its lofty valuation, especially considering three out of the past four quarters have been disappointing.

MAKO's quarter was similarly disappointing, but in this case the punishment didn't quite fit the crime. RIO system sales came in light and the company reduced its full-year system sales guidance, although on the bright side it stuck with its procedure outlook. The business continues to grow, and one bad quarter doesn't ruin MAKO's momentum. A deeper concern was the credit facility agreement that MAKO may need to tap if it needs cash, despite CFO Fritz LaPorte's comments a quarter prior that the company wouldn't need to tap the markets for capital.

The Street plain got it wrong with Universal Display's quarter. A quarter of sell-side analysts hadn't properly modeled Samsung's licensing payments this year, inflating the consensus estimates and leading to a "miss" on revenue. Sammy is forking over US$30 million this year, and analysts were expecting that in four even installments of US$7.5 million per quarter. Instead, UDC is getting US$15 million in the second and fourth quarters. Foolishly looking at the bigger picture, the company expects full year sales between US$90 million and US$110 million, representing between 47% and 79% growth from 2011. Hardly cause for panic there, if you ask me.

Exhibits A, B, and C
Here's how these companies' valuation multiples looked in the respective wakes of each release.


P/E the Day After Earnings

P/S the Day After Earnings

Riverbed Technology 54.5 4.2
MAKO Surgical NM 12.1
Universal Display 117.8 25.3

Sources: SEC filings, author's calculations. NM = not meaningful.

That's multiple compression if I've ever seen it. Furthermore, both Riverbed and MAKO have trended lower to new 52-week lows while Universal Display saw another patent scare, further disheartening this Fool. I knew what I was getting myself into with these risky picks, but that hardly makes the plunges sting less.

Sell-offs like these are part of the territory with high-multiple growth investing. In hindsight, perhaps I was a tad overweight in small-cap equities and should have diversified more into larger companies with less risk.

Down, but not out
Every investor is going to have days — and earnings seasons — like these, where your emotions take hold and make you want to sell out your entire equity portfolio and swear off the stock market for life.

The hard part is to tame those feelings, pick yourself back up, brush off the short-term movements, and focus on the long-term business. That's what being a Fool is all about. Me? I may be down on growth investing, but I'm not out.

If you're in the market for some high yielding ASX shares, look no further than our "Secure Your Future with 3 Rock-Solid Dividend Stocks" report. In this free report, we've put together our best ideas for investors who are looking for solid companies with high dividends and good growth potential. Click here now to find out the names of our three favourite income ideas. But hurry – the report is free for only a limited time.

 More reading

The Motley Fool's purpose is to help the world invest, better. Take Stock is The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. Click here now to request your free subscription, whilst it's still available. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

A version of this article, written by Evan Niu, originally appeared on fool.com

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »